12:00 AM
 | 
Aug 08, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Safinamide: Completed Phase III enrollment

Merck's Merck Serono S.A. division completed enrollment of 549 PD patients with motor fluctuations in the 6-month, double-blind, placebo-controlled, international Phase III SETTLE trial evaluating 50-100 mg oral safinamide once daily as add-on...

Read the full 151 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >